Skip to main content

Table 2 Baseline characteristics of participants, by reporting mode

From: Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation

  Internet Telephone Total
Completed, n (% of total) 290 (84.3%) 54 (15.7%) 344 (100%)
Completed by: n (%)    
   Patient 277 (95.5%) 54 (100%) 331 (96.2%)
   Carer 6 (2.1%) 0 (0%) 6 (1.7%)
   Parent 7 (2.4%) 0 (0%) 7 (2.0%)
Age, mean years (range) 51.4 (13-77)a 61.5 (35-82) 53.1 (13-82)
Sex, n (%) M/F 103/166 (38.3/61.7) 19/35 (35.2/64.8) 122/201 (37.8/62.2)
Diagnosis, n (%) [mean age, %F]    
   Rheumatoid arthritis 152 (79.6%) [53.9, 72%] 39 (20.4)% [64.4, 67%] 191 (100%)[56.0, 71%]
   Psoriasis 31 (88.6%) [48.2, 52%] 4 (11.4%) [61.2, 75%] 35 (100%) [49.8, 62%]
   Ankylosing spondylitis 40 (93.0%)[49.1, 25%] 3 (7.0%) [51.3, 33%] 43 (100%) [49.2, 26%]
   Psoriatic arthritis 37 (84.1%) 50.3, 68%] 7 (15.9%) [51.9, 71%] 44 (100%) [50.5, 68%]
   Otherb 30 (96.8%) [41.7, 63%] 1 (3.2%) [48.0, 0%] 31 (100%) [42.1, 62%]
Previous biologics    
   N 275 54 329
   Any 59 (21.5%) 6 (11.1%) 65 (19.8%)
   Adulimumab 43 (15.6%) 5 (9.3%) 48 (14.6%)
   Infliximab 11 (4.0%) 1 (1.9%) 12 (3.6%)
Current medications    
   N 277 54 331
   Methotrexate 120 (43.3%) 29 (53.7%) 149 (45.0%)
   Sulfasalazine 46 (16.6%) 7 (13.0%) 53 (16.0%)
   Prednisolone 55 (19.9%) 14 (25.9%) 69 (20.8%)
Quality of life    
CGI-S    
   N 275 54 329
   N ( %) ≥markedly ill) 184 (66.9%) 30 (55.6%) 214 (65.0%)
EQ-5D    
   N 265 54 (0.35)
   EQ5D Index, Mean (SD) 0.41 (0.36) 0.45 (0.29) 0.42
   N 139 20 159
   EQ5D VAS, Mean (SD) 47.6 (23.0) 51.2 (21.8) 48.1 (22.8)
HAQ    
   N 151   190
   Mean (SD) 1.68 (0.64)c 1.97 1.74 (0.65)
DLQI    
   N 31 4 35
   Mean (SD) 15.5 (8.1) 11.8 (3.4) 15.0 (7.8)
  1. a Statistically significant difference between Internet and telephone users, p < 0.001 (Wilcoxon test)
  2. b Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition missing (n = 12, 3.5%) to the question 'What condition do you have that is being treated with Enbrel?'
  3. c Statistically significant difference between Internet and telephone users, p = 0.003 (Wilcoxon test), p = 0.010 (t-test)